Bluebird Bio Inc. (NASDAQ:BLUE)

CAPS Rating: 4 out of 5

Results 1 - 20 of 21 : 1 2 Next »

Recs

0
Member Avatar cmrk3 (< 20) Submitted: 4/30/2016 3:40:43 PM : Outperform Start Price: $44.87 BLUE Score: +1.72

Gene-therapy

Recs

0
Member Avatar gcaderas (71.79) Submitted: 3/11/2016 5:41:04 AM : Underperform Start Price: $45.77 BLUE Score: +3.12

Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $-1.21 $-1.27 $-5.26 $-5.90
Number of Analysts 11 9 11 10
High Estimate $-0.77 $-0.83 $-3.54 $-4.08
Low Estimate $-1.41 $-1.45 $-6.15 $-7.16
Prior Year $-0.75 $-1.51 $-4.75 $-5.26
Growth Rate (Year over Year) -60.73% 16.11% -10.72% -12.21%

Recs

0
Member Avatar Exanut (< 20) Submitted: 1/17/2016 11:32:08 AM : Outperform Start Price: $45.34 BLUE Score: -8.31

They have pulled off what no other company was able to do successfully to date: gene therapy. This is a paradigm shift in treating hereto untreateable diseases. I don't expect the road to be easy as far as investing with this company, but I do think that if BLUE proves to be even somewhat successful this has a potential to dramatically change medicine forever, and give significant investor returns in the process. this is still early in the story, and as we have seen, stock prices can swing dramatically because there is still so much unknown for this technology and the company in general. I for one, am willing to take the risk.

Recs

0
Member Avatar iksnamyzs (69.65) Submitted: 11/23/2015 12:21:35 AM : Outperform Start Price: $80.90 BLUE Score: -42.63

speculation

Recs

0
Member Avatar TSIF (99.95) Submitted: 11/16/2015 2:40:45 PM : Outperform Start Price: $70.16 BLUE Score: -33.84

Didn't ride this one like I should have years ago...but at least didn't have to ride the waves....

Down 20% because a gene therapy has varying results on a malady that has various manifestations genetically...hmmm...should a one size fit all? Can they get hit enough of the variations to productize??
May reduce transfusions even when it isn't a cure.

Limited Data, but well funded, wide platform, but gene therapies to date have not panned out.

Risk / reward...an individual call.
Think I'll get on the wave here....

Recs

0
Member Avatar coptermech66 (< 20) Submitted: 10/29/2015 3:09:55 PM : Underperform Start Price: $79.54 BLUE Score: +41.93

Blue is crap!

Recs

1
Member Avatar 1russianguy (47.71) Submitted: 8/20/2015 3:21:55 PM : Outperform Start Price: $118.85 BLUE Score: -64.50

Playing for a bounce from a correction.

Recs

1
Member Avatar TMFInnovator (31.91) Submitted: 8/17/2015 2:27:36 PM : Outperform Start Price: $135.99 BLUE Score: -65.70

Re-opening this after the recent sell-off. Still think this company has huge long-term opportunities in CAR-T and gene editing.

http://www.bluebirdbio.com/our-focus/

Recs

1
Member Avatar sullyz0r (33.60) Submitted: 7/13/2015 3:42:28 PM : Outperform Start Price: $163.55 BLUE Score: -71.06

Hopping back on the BLUE gravy train

Recs

0
Member Avatar laurao444 (< 20) Submitted: 5/19/2015 7:40:37 PM : Outperform Start Price: $173.89 BLUE Score: -71.19

They're in phase II/III trials for sickle cell and other rare blood diseases in collaboration with a larger biotech (which one Novartis? - I've forgotten since I did the research but have been following them for a while). Are on track to meet development milestones for which they'll receive payments and look like a good acquisition.

Recs

2
Member Avatar portefeuille (99.10) Submitted: 5/10/2015 4:08:21 AM : Outperform Start Price: $21.44 BLUE Score: +101.13

Now 200 BLUE shares in the #zzporte portfolio, in the green by around $38k.
https://twitter.com/portefeuillefun/status/597067869051068416.

Recs

0
Member Avatar Herbstmd (37.41) Submitted: 5/7/2015 4:00:24 PM : Outperform Start Price: $155.00 BLUE Score: -69.03

A great deal of promise inngenenetic alteration of disease states like sickle cell.

Recs

0
Member Avatar gideonstrauss (55.81) Submitted: 5/4/2015 4:51:04 PM : Outperform Start Price: $132.22 BLUE Score: -63.86

Hardcore healthy-making research sets Bluebird Bio up for a big future of SOME kind, and one of my CAPS nods to the Rulebreaker core portfolio suggestions.

Recs

0
Member Avatar MoeBruin (73.83) Submitted: 4/28/2015 12:44:34 PM : Outperform Start Price: $133.94 BLUE Score: -64.21

Cancer drugs are making breakthroughs. This stock is advanced.

Recs

0
Member Avatar stockgeek623 (< 20) Submitted: 3/28/2015 8:56:41 AM : Underperform Start Price: $117.01 BLUE Score: +61.28

I feel that biotechnology stocks always underperform at the peak market levels and try to boost their performance as trading goes on.

Recs

1
Member Avatar Gibbs721 (21.20) Submitted: 2/6/2015 10:44:32 AM : Outperform Start Price: $85.01 BLUE Score: -48.03

Early results from attempts to cure hereditary diseases using genetic treatment look promising. Continued success would be a huge breakthrough with great potential for further developments and success.

Recs

0
Member Avatar MotleyFolJohn (< 20) Submitted: 2/2/2015 11:02:22 AM : Underperform Start Price: $93.98 BLUE Score: +55.34

The Bio Sector will out perform the 2015 NASDAQ However, BlueBird Bio will under perform.
Happy Investing

Recs

1
Member Avatar SkepBioInvestor (93.20) Submitted: 6/26/2014 5:21:15 PM : Outperform Start Price: $39.88 BLUE Score: +8.36

Wall St darling

Recs

1
Member Avatar loangolfer (< 20) Submitted: 1/17/2014 8:43:56 AM : Outperform Start Price: $24.26 BLUE Score: +76.11

ZZ likes it......

Recs

10
Member Avatar zzlangerhans (99.78) Submitted: 8/22/2013 1:17:56 AM : Outperform Start Price: $27.03 BLUE Score: +44.34

There's some companies I study fairly vigorously before I start nattering about them and some I don't. Bluebird falls into the latter category. There's not much I can do - I'm just one guy trying to follow 250 stocks plus I have two babies who think Dad's laptop is the greatest toy in the world. All I can say about Bluebird is that they're developing lentoviral vectors, which I believe are the vectors you use when you've given up other viral vectors for Lent. Bluebird has one trial in progress for a lentoviral gene therapy of beta thalassemia and another planned to begin in mid-2013, and they're planning to initiate a phase II/III trial of another lentoviral gene therapy for childhood cerebral adrenoleukodystrophy in late 2013.

I happen to own 40 shares of Bluebird bought at the absolute all time high of 36 on July 17, courtesy of Portefeuille. I don't mean to razz him too much; that doesn't happen very often. The stock's been in a pretty nasty declining trend since then but I have a feeling things will pick back up before long. Hopefully by then I'll have had time to brush up a little on what this company actually does.

Results 1 - 20 of 21 : 1 2 Next »

Featured Broker Partners